We are live on ! Find out more
WIM

Woodford Investment Management Portfolio holdings

AUM $310M
1-Year Est. Return 17.41%
This Fund
S&P 500
This Quarter Est. Return
-22.25%
1 Year Est. Return
-17.41%
3 Year Est. Return
-27.14%
5 Year Est. Return
+68.29%
10 Year Est. Return
–
AUM
$825M
AUM Growth
-$300M
Cap. Flow
+$90.3M
Cap. Flow %
10.94%
Top 10 Hldgs %
100%
Holding
10
New
4
Increased
4
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
AUTL
Autolus Therapeutics
AUTL
+$42.1M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$34M
3
EVFM
Evofem Biosciences, Inc. Common Stock
EVFM
+$11.2M
4
TBPH icon
Theravance Biopharma
TBPH
+$7.48M
5
PRTA icon
Prothena Corp
PRTA
+$7.25M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$25.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.19%
2 Consumer Staples 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBPH icon
1
Theravance Biopharma
TBPH
$877M
$254M 30.84%
11,213,879
+315,000
+3% +$7.48M
ALKS icon
2
Alkermes
ALKS
$8.25B
$194M 23.54%
4,717,010
-553,418
-11% -$25.2M
PRTA icon
3
Prothena Corp
PRTA
$450M
$174M 21.08%
11,924,614
+367,000
+3% +$7.25M
BIIB icon
4
Biogen
BIIB
$30.7B
$81.1M 9.84%
279,564
– –
AUTL
5
Autolus Therapeutics
AUTL
$562M
$42.6M 5.17%
+1,591,743
New +$42.1M
AGIO icon
6
Agios Pharmaceuticals
AGIO
$1.93B
$32.8M 3.98%
+390,000
New +$34M
EVFM
7
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$26M 3.15%
639,546
+141,843
+28% +$11.2M
NCNA
8
NuCana
NCNA
$6.12M
$7.98M 0.97%
84
+18
+27% +$2.22M
MO icon
9
Altria Group
MO
$114B
$6.7M 0.81%
+118,000
New +$6.81M
NITE
10
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$5.02M 0.61%
+314,000
New +$4.48M

Similar funds

LCM
Lucha Capital Management San Francisco, California $327M AUM 2.87% 1-Year Est. Return
GWA
Guidant Wealth Advisors Palatine, Illinois $269M AUM 2.79% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
IPC
Invesco Private Capital New York $365M AUM 8.08% 1-Year Est. Return
AEPG
American Economic Planning Group Warren, New Jersey $367M AUM 2.51% 1-Year Est. Return
AR
Argyll Research Wilmington, Delaware $377M AUM 4.86% 1-Year Est. Return
KCM
Keywise Capital Management Grand Cayman, Cayman Islands $220M AUM 21.27% 1-Year Est. Return
COI
Capital One Investing Mclean, Virginia $430M AUM 3.49% 1-Year Est. Return

Woodford Investment Management's Q2 2018 Portfolio in Review

As of Q2 2018, Woodford Investment Management held 10 positions worth $825M, down 27% from $1.12B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Woodford Investment Management deployed $90.3M of net new capital in Q2 2018, opening 4 new positions and adding to 4 existing holdings. Its largest new stake was Autolus Therapeutics: 1,591,743 shares worth $42.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Alkermes, an estimated $25.2M trimmed.

  • Woodford Investment Management's largest Q2 2018 buy was Autolus Therapeutics: 1,591,743 shares worth $42.6M.
  • Woodford Investment Management added most to Evofem Biosciences, Inc. Common Stock in Q2 2018, an estimated $11.2M increase.
  • Woodford Investment Management's biggest Q2 2018 reduction was Alkermes, cutting an estimated $25.2M.
  • Woodford Investment Management's ten largest holdings make up 100% of its $825M portfolio in Q2 2018.
  • Woodford Investment Management opened 4 new positions and closed 0 in Q2 2018.
  • Woodford Investment Management's portfolio value fell 27% quarter-over-quarter to $825M.

Based on Woodford Investment Management's 13F filing for Q2 2018, filed 9 Aug 2018.